Showing results (421-430 of 464) with videos related to

Sort By:
Pageof 47
The Journal of Clinical Investigation|March 14, 2018
Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitmentJessica Wagner, C Leah Kline, Lanlan Zhou, et al.
Frontiers in Oncology|May 11, 2023
ERBB family fusions are recurrent and actionable oncogenic targets across cancer typesLaura Schubert, Andrew Elliott, Anh T Le, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2025
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical TrialsJia Liu, Max Farrow, Lesley Seymour, et al.
Eclinicalmedicine|March 5, 2026
Tumor antigen only (TAO) vaccine platforms for glioblastoma therapeutics: a systematic review of evidence from clinical trialsHsien-Chung Chen, Eric T Wong, Sasmit Sarangi, et al.
Cancer Research|June 8, 2011
Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1Patrick A Mayes, Nathan G Dolloff, Colin J Daniel, et al.
Plos One|August 3, 2017
Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumorsVarun V Prabhu, Amriti R Lulla, Neel S Madhukar, et al.
ESMO Open|November 24, 2020
Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinomaAndreas Seeber, Kai Zimmer, Florian Kocher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2022
Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic AdenocarcinomaPhilip A Philip, Ibrahim Azar, Joanne Xiu, et al.
Biorxiv : the Preprint Server for Biology|August 15, 2020
Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cellsLanlan Zhou, Kelsey Huntington, Shengliang Zhang, et al.
Oncotarget|November 27, 2020
MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infectionLanlan Zhou, Kelsey Huntington, Shengliang Zhang, et al.
Pageof 47